NXL Stock Overview A medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. More details
Rewards Risk Analysis + 1 more risk
See All Risk Checks Capture your thoughts, links and company narrative
Nexalin Technology, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Nexalin Technology Historical stock prices Current Share Price US$3.72 52 Week High US$4.49 52 Week Low US$0.25 Beta 4.26 1 Month Change 25.25% 3 Month Change -2.11% 1 Year Change 1,119.27% 3 Year Change n/a 5 Year Change n/a Change since IPO 65.33%
Recent News & Updates
Nexalin Technology, Inc. Completes Phase 1 of Its Innovative Virtual Clinic Dec 24
Nexalin Technology (NASDAQ:NXL) Is In A Good Position To Deliver On Growth Plans Nov 29
New major risk - Shareholder dilution Nov 22
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2) Nov 01
New major risk - Revenue and earnings growth Oct 09 See more updates
Nexalin Technology, Inc. Completes Phase 1 of Its Innovative Virtual Clinic Dec 24
Nexalin Technology (NASDAQ:NXL) Is In A Good Position To Deliver On Growth Plans Nov 29
New major risk - Shareholder dilution Nov 22
Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind Nov 10
Nexalin Technology Regains Compliance with Nasdaq’s Minimum Bid Price Requirement under Nasdaq Rule 5550(a)(2) Nov 01
New major risk - Revenue and earnings growth Oct 09
Nexalin Technology Receives Non-Compliance Notice from Nasdaq Regarding Minimum Bid Price Requirement Sep 25
Second quarter 2024 earnings released: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023) Aug 11
New major risk - Market cap size Aug 09
Nexalin Technology, Inc., Annual General Meeting, Aug 26, 2024 Jul 30 Nexalin Technology, Inc. has completed a Follow-on Equity Offering in the amount of $5.25 million. Jul 02
Nexalin Technology Announces Positive Clinical Study Data in Major Depressive Disorder and Publication of Clinical Trial Results in Leading Scientific Journal Jun 26
Nexalin Technology, Inc. Announces FDA Provides Feedback and Reaches Consensus on Nexalin's Design for Planned Anxiety and Insomnia Clinical Studies of its Gen-3 Halo Clarity Headset Device Jun 05 Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $7 million. May 24
Nexalin Technology, Inc. Provides Non-Compliance Update May 22
First quarter 2024 earnings released: US$0.14 loss per share (vs US$0.10 loss in 1Q 2023) May 13
Nexalin Technology, Inc. Regains Compliance with Nasdaq Continued Listing Requirements Apr 27 Nexalin Technology, Inc. has filed a Follow-on Equity Offering in the amount of $5.646485 million. Apr 16
Nexalin Technology Accelerates Manufacturing of Its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing Apr 12
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board Apr 02
Full year 2023 earnings released: US$0.63 loss per share (vs US$0.30 loss in FY 2022) Mar 29
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego Mar 28
Nexalin Technology, Inc. Announces Positive Results from Clinical Study of Its Gen-2 Tacs Device for Treating Adult Patients with Chronic Insomnia Mar 07
Nexalin Technology Announces Regulatory Approval in Oman for Gen-2 Neurostimulation Device Feb 09
Nexalin Technology, Inc. Unveils Gen-3 HALO™? Clarity 15 Milliamp Neurostimulation Device Jan 11
Third quarter 2023 earnings released: US$0.31 loss per share (vs US$0.026 loss in 3Q 2022) Nov 16
Nexalin Technology Receives Written Notice from the Nasdaq Listing Qualifications Department Regarding Not Eligible for an Additional 180 Calendar Day Compliance Period Nov 14
Nexalin Technology, Inc. Announces Publication of Deep-Brain Stimulation Study in Leading Peer-Reviewed Journal Oct 17
Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023 Oct 08
Nexalin Technology, Inc., Annual General Meeting, Nov 10, 2023 Oct 07
Second quarter 2023 earnings released: US$0.11 loss per share (vs US$0.09 loss in 2Q 2022) Aug 13
Nexalin Technology Reports Results of Clinical Study Supporting the Therapeutic Benefits of Its Gen-2, 15 Milliamp Neurostimulation Device in Treating Migraine Headaches and Related Symptoms Aug 08
Nexalin Technology, Inc. Receives Written Notice from the Nasdaq Stock Market Regarding Minimum Bid Price Requirement May 17
First quarter 2023 earnings released: US$0.10 loss per share (vs US$0.08 loss in 1Q 2022) May 13
Full year 2022 earnings released: US$0.30 loss per share (vs US$1.43 loss in FY 2021) Mar 29
Nexalin Technology, Inc. Appoints Michael Nketiah as Senior Vice President of Quality, Clinical and Regulatory Jan 25
Insufficient new directors Nov 16
Third quarter 2022 earnings released: US$0.026 loss per share (vs US$0.40 loss in 3Q 2021) Nov 12
Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million. Sep 21
Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million. Sep 20 Nexalin Technology, Inc. has completed an IPO in the amount of $9.60725 million. Sep 17
Insufficient new directors Sep 16 Shareholder Returns NXL US Medical Equipment US Market 7D 27.4% -0.9% 0.2% 1Y 1,119.3% 12.5% 22.0%
See full shareholder returns
Return vs Market: NXL exceeded the US Market which returned 22% over the past year.
Price Volatility Is NXL's price volatile compared to industry and market? NXL volatility NXL Average Weekly Movement 15.3% Medical Equipment Industry Average Movement 8.8% Market Average Movement 6.1% 10% most volatile stocks in US Market 18.6% 10% least volatile stocks in US Market 3.1%
Stable Share Price: NXL's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: NXL's weekly volatility has decreased from 34% to 15% over the past year, but is still higher than 75% of US stocks.
About the Company Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer’s disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues.
Show more Nexalin Technology, Inc. Fundamentals Summary How do Nexalin Technology's earnings and revenue compare to its market cap? NXL fundamental statistics Market cap US$47.33m Earnings (TTM ) -US$5.55m Revenue (TTM ) US$162.08k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) NXL income statement (TTM ) Revenue US$162.08k Cost of Revenue US$34.33k Gross Profit US$127.75k Other Expenses US$5.68m Earnings -US$5.55m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -0.43 Gross Margin 78.82% Net Profit Margin -3,427.10% Debt/Equity Ratio 0%
How did NXL perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/02/07 23:08 End of Day Share Price 2025/02/07 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github .
Analyst Sources Nexalin Technology, Inc. is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Anthony Vendetti Maxim Group
